However, its potential role in mediating chemotherapy resistance is poorly defined.<h4>Aims</h4>This study aimed to elucidate the mechanism by which NFIB regulates chemoresistance in SCLC and to assess the therapeutic potential of co-targeting NFIB and the Notch signaling pathway.<h4>Methods and results</h4>Expression of NFIB and associated genes was analyzed in SCLC cell lines and clinical samples using Western blotting, quantitative real-time PCR (qRT-PCR), immunofluorescence (IF), and immunohistochemistry (IHC). The gene discussed is NFIB; the disease is small cell lung carcinoma.